In­hi­brx’s ear­ly col­orec­tal can­cer da­ta cloud­ed by pa­tient death

One of In­hi­brx Bio­sciences’ an­ti­body can­di­dates has shown en­cour­ag­ing ear­ly ef­fi­ca­cy in col­orec­tal can­cer. But its safe­ty is un­der scruti­ny af­ter a pa­tient en­rolled in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER